Advertisement

Topics

Apollo Endosurgery, Inc. Reports Fourth Quarter and Full Year 2016 Results

16:02 EST 8 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Endo-bariatric Sales Growth of 26% in the Fourth Quarter and 86% for the Full Year Conference Call to Discuss Results Today at 3:30 p.m. CT / 4:30 p.m. ET Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a ...

Other Sources for this Article

Apollo Endosurgery, Inc.
Stefanie Cavanaugh, 512-279-5100
Chief Financial Officer
investor-relations@apolloendo.com
or
The Ruth Group
Nick Laudico or Zack Kubow, 646-536-7000
apolloendo@theruthgroup.com

NEXT ARTICLE

More From BioPortfolio on "Apollo Endosurgery, Inc. Reports Fourth Quarter and Full Year 2016 Results"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...